Literature DB >> 23556053

Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer.

Xiao-Zhong Guo1, Zhong-Min Cui, Xu Liu.   

Abstract

Pancreatic cancer is a common malignant neoplasm of the pancreas with an increasing incidence, a low early diagnostic rate and a fairly poor prognosis. To date, the only curative therapy for pancreatic cancer is surgical resection, but only about 20% patients have this option at the time of diagnosis and the mean 5-year survival rate after resection is only 10%-25%. Therefore, developing new treatments to improve the survival rate has practical significance for patients with this disease. This review deals with a current unmet need in medical oncology: the improvement of the treatment outcome of patients with pancreatic cancer. We summarize and discuss the latest systemic chemotherapy treatments (including adjuvant, neoadjuvant and targeted agents), radiotherapy, interventional therapy and immunotherapy. Besides discussing the current developments, we outline some of the main problems, solutions and prospects in this field.

Entities:  

Keywords:  Immunotherapy; Interventional therapy; Pancreatic cancer; Radiotherapy; Survival rate; Systemic chemotherapy; Treatment

Year:  2013        PMID: 23556053      PMCID: PMC3613767          DOI: 10.4251/wjgo.v5.i2.20

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  36 in total

1.  Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial.

Authors:  S Boeck; K Weigang-Köhler; M Fuchs; E Kettner; D Quietzsch; J Trojan; O Stötzer; S Zeuzem; F Lordick; C-H Köhne; H Kröning; T Steinmetz; H Depenbrock; V Heinemann
Journal:  Ann Oncol       Date:  2007-01-17       Impact factor: 32.976

Review 2.  Interventional EUS for the treatment of pancreatic cancer.

Authors:  Reiko Ashida; Kenneth J Chang
Journal:  J Hepatobiliary Pancreat Surg       Date:  2009-06-23

3.  Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma.

Authors:  Morten Hoyer; Henrik Roed; Lisa Sengelov; Anders Traberg; Lars Ohlhuis; Jorgen Pedersen; Hanne Nellemann; Anne Kiil Berthelsen; Frey Eberholst; Svend Aage Engelholm; Hans von der Maase
Journal:  Radiother Oncol       Date:  2005-07       Impact factor: 6.280

4.  Preoperative interleukin-2 immunotherapy in pancreatic cancer: preliminary results.

Authors:  Carlo Angelini; Giorgio Bovo; Pietro Muselli; Chiara Mussi; Stefano Crippa; Roberto Caprotti; Franco Uggeri
Journal:  Hepatogastroenterology       Date:  2006 Jan-Feb

Review 5.  Monoclonal antibody therapies targeting pancreatic ductal adenocarcinoma.

Authors:  Kevin Engelhardt; Christopher Riley; Laurence Cooke; Daruka Mahadevan
Journal:  Curr Drug Discov Technol       Date:  2006-12

6.  Comparison of intrahepatic and pancreatic perfusion on fusion images using a combined SPECT/CT system and assessment of efficacy of combined continuous arterial infusion and systemic chemotherapy in advanced pancreatic carcinoma.

Authors:  Osama Ikeda; Yoshitaka Tamura; Yutaka Nakasone; Shinya Shiraishi; Kouichi Kawanaka; Seiji Tomiguchi; Yasuyuki Yamashita; Hiroshi Takamori; Keiichiro Kanemitsu; Hideo Baba
Journal:  Cardiovasc Intervent Radiol       Date:  2007-08-21       Impact factor: 2.740

7.  HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.

Authors:  Marianne Klemp Gjertsen; Ingvil Saeterdal; Stein Saebøe-Larssen; Gustav Gaudernack
Journal:  J Mol Med (Berl)       Date:  2002-11-13       Impact factor: 4.599

8.  Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer.

Authors:  Seong Yoon Yi; Young Suk Park; Hyo Song Kim; Hyun Jung Jun; Kyoung Ha Kim; Myung Hee Chang; Min Jae Park; Ji Eun Uhm; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Jong Kyun Lee; Kyu Taek Lee; Ho Yeong Lim; Won Ki Kang
Journal:  Cancer Chemother Pharmacol       Date:  2008-10-07       Impact factor: 3.333

9.  Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model.

Authors:  C Schneider; T Schmidt; C Ziske; K Tiemann; K-M Lee; V Uhlinsky; P Behrens; T Sauerbruch; I G H Schmidt-Wolf; P F Mühlradt; J Schmidt; A Märten
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

Review 10.  Preoperative tissue diagnosis for tumours of the pancreas.

Authors:  W Hartwig; L Schneider; M K Diener; F Bergmann; M W Büchler; J Werner
Journal:  Br J Surg       Date:  2009-01       Impact factor: 6.939

View more
  7 in total

Review 1.  Pancreatic cancer.

Authors:  C Güngör; B T Hofmann; G Wolters-Eisfeld; M Bockhorn
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 2.  Current status and progress of pancreatic cancer in China.

Authors:  Quan-Jun Lin; Feng Yang; Chen Jin; De-Liang Fu
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

Review 3.  Pancreatic cancer: diagnosis and treatments.

Authors:  Hong-Yu Li; Zhong-Min Cui; Jiang Chen; Xiao-Zhong Guo; Ying-Yi Li
Journal:  Tumour Biol       Date:  2015-02-14

4.  Hellebrigenin anti-pancreatic cancer effects based on apoptosis and autophage.

Authors:  Xiaolu Wei; Jing He; Bo Gao; Lingyu Han; Yingqiu Mao; Haiyu Zhao; Nan Si; Hongjie Wang; Jian Yang; Baolin Bian
Journal:  PeerJ       Date:  2020-05-08       Impact factor: 2.984

Review 5.  Current status of non-surgical treatment of locally advanced pancreatic cancer.

Authors:  Stavros Spiliopoulos; Maria Teresa Zurlo; Annachiara Casella; Letizia Laera; Giammarco Surico; Alessia Surgo; Alba Fiorentino; Nicola de'Angelis; Roberto Calbi; Riccardo Memeo; Riccardo Inchingolo
Journal:  World J Gastrointest Oncol       Date:  2021-12-15

6.  Rhoifolin from Plumula Nelumbinis exhibits anti-cancer effects in pancreatic cancer via AKT/JNK signaling pathways.

Authors:  Bingxin Zheng; Yixin Zheng; Ningning Zhang; Yi Zhang; Baodong Zheng
Journal:  Sci Rep       Date:  2022-04-05       Impact factor: 4.996

7.  LyP-1-fMWNTs enhanced targeted delivery of MBD1siRNA to pancreatic cancer cells.

Authors:  Quan-Jun Lin; Zhi-Bo Xie; Ya Gao; Yi-Fan Zhang; Lie Yao; De-Liang Fu
Journal:  J Cell Mol Med       Date:  2020-01-22       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.